---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-022505"
form_type: "8-K"
ticker: "MGRX"
cik: "0001938046"
company_name: "MANGOCEUTICALS, INC."
filed_at: "2025-11-14T23:59:59+00:00"
generated_at: "2026-05-16T19:56:28.586792+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Mangoceuticals clarifies GLP-1 programs: no direct contracts with Eli Lilly or Novo Nordisk

## Summary
- MangoRx Direct and PeachesRx Direct can prescribe branded GLP-1s (Zepbound, Wegovy) via third-party provider.
- Company has no direct contractual relationship with Eli Lilly or Novo Nordisk; access is through an independent provider.
- Programs launched Nov 13, 2025 at $99/month; medication cost and fulfillment separate.
- Clarification follows earlier press release that may have implied direct partnerships.

## SEC filing metadata
- accession: 0001493152-25-022505
- form_type: 8-K
- ticker: MGRX
- cik: 0001938046
- company_name: MANGOCEUTICALS, INC.
- filed_at: 2025-11-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1938046/000149315225022505/0001493152-25-022505-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1938046/000149315225022505/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-022505
- JSON: https://secwatch.observer/filing/0001493152-25-022505.json
- Plain text: https://secwatch.observer/filing/0001493152-25-022505.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.